Immunocompetent mouse models with a triple negative breast tumor (4T1) when treated with GRID and antibodies against immune checkpoints PD1 and CTLA-4 showed that a systemic immune activation to a primary tumor, can promote anti-tumor immune responses outside the radiation field [102]. The gene discussed is CTLA4; the disease is neoplasm.